Replies to post #76 on VolitionRX Limited (VNRX)

[rodman]

All hype or is the $4. pps a break out point? The investment tour seems to have elevated VNRX temporarily. My buy in add-on point
just dropped to $3.40 ( Just my opinion) breaking out & running past $4 with news.

http://www.volitionrx.com/news/presentations

Here is why:

Corporate Highlights
• Emerging leader in blood-based cancer diagnostics
• Large global market opportunity
• Compelling clinical and economic solution
• NuQ® has potential as platform technology
• Multiple near-term clinical and corporate milestones
• NYSE MKT listed
• Funded through to 2H 2016

Main Competitors – Colorectal Cancer
1. Initial data release from retrospective study released on September 11, 2014 Source: Company reports
Emerging IVD Technologies Current Industry Standards
VolitionRx1
NuQ®
EpiGenomics
(Epi proColon)
Exact Sciences
DNA Cologuard Colonoscopy
FOBT (Fecal
Occult)
FIT (Fecal
Immunochemical)

CRC Sensitivity 84% 68% 92% 95% 13% 66%
Pre – Cancer Polyp
Sensitivity 60% 20% 42% 95% 11% 22%
Specificity 78% 78% 87% 90% 95% 95%
Price (Physician/Lab) TBD $150 $493 $1,000+ $5 $23
Primary Exchange:
Ticker
NYSE MKT:
VNRX XETRA:ECX NASDAQ:EXAS
Market Cap at
5/15/2015 $63M $93M $2.04